CN Patent

CN107698563B — 制备马来酸来那替尼晶型的方法

Assigned to Arizest Shanghai Pharmatech Co ltd · Expires 2020-10-30 · 6y expired

What this patent protects

本发明涉及制备马来酸来那替尼晶型的方法。具体地，本发明方法采用低沸点的混合溶剂，溶剂容易去除、残留少，并且直接析晶，摆脱了通过干燥来控制转晶的依赖，操作方式简便，工艺条件温和。同时，本发明方法可在常温下进行，不需加热和冷却，制备工艺简单高效、重复性好、成本低廉、收率高，适合大规模工业化生产。通过本发明方法制备的晶体，纯度高、结晶度高、溶剂残留符合要点要求、粒度和形貌可控。

USPTO Abstract

本发明涉及制备马来酸来那替尼晶型的方法。具体地，本发明方法采用低沸点的混合溶剂，溶剂容易去除、残留少，并且直接析晶，摆脱了通过干燥来控制转晶的依赖，操作方式简便，工艺条件温和。同时，本发明方法可在常温下进行，不需加热和冷却，制备工艺简单高效、重复性好、成本低廉、收率高，适合大规模工业化生产。通过本发明方法制备的晶体，纯度高、结晶度高、溶剂残留符合要点要求、粒度和形貌可控。

Drugs covered by this patent

Patent Metadata

Patent number
CN107698563B
Jurisdiction
CN
Classification
—
Expires
2020-10-30
Drug substance claim
No
Drug product claim
No
Assignee
Arizest Shanghai Pharmatech Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.